[go: up one dir, main page]

IN2012DN02624A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02624A
IN2012DN02624A IN2624DEN2012A IN2012DN02624A IN 2012DN02624 A IN2012DN02624 A IN 2012DN02624A IN 2624DEN2012 A IN2624DEN2012 A IN 2624DEN2012A IN 2012DN02624 A IN2012DN02624 A IN 2012DN02624A
Authority
IN
India
Prior art keywords
animals
day
amounts
preventing
comprise administering
Prior art date
Application number
Inventor
Yuanlong Pan
Sunil Kochhar
Serge Andre Dominique Rezzi
Francoise-Pierre Martin
Emma Pere-Trepat
Sebastiano Collino
Vera Francia Arce
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of IN2012DN02624A publication Critical patent/IN2012DN02624A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides methods for one or more of preventing or treating sarcopenia and muscle atrophy in animals. The methods comprise administering isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day.
IN2624DEN2012 2009-10-09 2010-10-08 IN2012DN02624A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27863309P 2009-10-09 2009-10-09
PCT/US2010/002722 WO2011043827A1 (en) 2009-10-09 2010-10-08 Methods for preventing or treating sarcopenia and muscle atrophy in animals

Publications (1)

Publication Number Publication Date
IN2012DN02624A true IN2012DN02624A (en) 2015-05-22

Family

ID=43857050

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2624DEN2012 IN2012DN02624A (en) 2009-10-09 2010-10-08

Country Status (12)

Country Link
US (1) US9301941B2 (en)
EP (1) EP2485740B1 (en)
JP (1) JP6122638B2 (en)
CN (1) CN102573857A (en)
AU (1) AU2010303872B2 (en)
BR (1) BR112012008238A2 (en)
CA (1) CA2776950C (en)
ES (1) ES2688447T3 (en)
IN (1) IN2012DN02624A (en)
MX (1) MX2012004118A (en)
RU (1) RU2558534C2 (en)
WO (1) WO2011043827A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
JP6001060B2 (en) 2011-06-06 2016-10-05 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Methods for inhibiting muscle atrophy
CN105708834A (en) * 2011-10-18 2016-06-29 株式会社爱茉莉太平洋 Sirt1 activator including syringaresinol
CN106255504A (en) * 2014-04-28 2016-12-21 三得利控股株式会社 Amyotrophy inhibitor containing quercetin glycoside
AU2016219070B2 (en) 2015-02-13 2020-06-11 Mars, Incorporated Pet food feeding system
KR20170002846A (en) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 Composition containing extract of soybean leaves for suppressing and preventing myopathy
GB201522304D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product for reducing muscle breakdown
GB201721627D0 (en) 2017-12-21 2018-02-07 Mars Inc Pet food product
CN108635571B (en) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 Application of irisin in the preparation of drugs for the prevention and treatment of severe acute pancreatitis
EP4039329A4 (en) * 2019-10-04 2023-08-02 Suntory Holdings Limited Composition for suppression of decrease in muscle mass, prevention of decrease therein, maintenance thereof, recovery thereof or increase therein
KR102623198B1 (en) * 2020-02-26 2024-01-10 한국 한의학 연구원 Compositions for preventing, ameliorating or treating for muscle strengthening, muscle development, muscle differentiation, muscle regeneration or sarcopenia comprising Glycine soja extract as effective component
RU2756154C1 (en) * 2020-11-13 2021-09-28 Митхат Зульфугар-Оглы Гасанов Method for diagnosing sarcopenia in patients with stage 5 chronic kidney disease receiving treatment with long-term hemodialysis
KR102803173B1 (en) * 2021-02-22 2025-05-07 한국 한의학 연구원 Composition for muscle strengthening, muscle development, muscle differentiation, muscle regeneration, for preventing, ameliorating or treating sarcopenia or muscle fatigue comprising compound isolated from Astragalus membranaceus extract as effective component
WO2023140407A1 (en) * 2022-01-21 2023-07-27 경상국립대학교병원 Pharmaceutical composition comprising coumestrol for preventing or treating sarcopenia
KR102803976B1 (en) * 2022-04-06 2025-05-07 국립강릉원주대학교산학협력단 Composition for strengthening muscle strength comprising extract of Styrax japonicas leaf extract
WO2025121473A1 (en) * 2023-12-06 2025-06-12 경상국립대학교병원 Pharmaceutical composition for preventing or alleviating sarcopenia, comprising acetylgenistin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166380B (en) 1973-07-09 1975-03-28
US6887499B2 (en) * 2000-05-22 2005-05-03 Enitan A. Bababunmi Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
IL145540A0 (en) * 2000-09-28 2002-06-30 Pfizer Prod Inc Use of growth hormone secretagogues in conjunction with physical exercise
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
JP5384777B2 (en) * 2001-12-18 2014-01-08 有限会社大長企画 Strong muscle agent, anti-inflammatory agent
WO2005007676A2 (en) * 2003-07-10 2005-01-27 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
US20050256181A1 (en) * 2004-01-29 2005-11-17 Elixir Pharmaceuticals, Inc. Treating a viral disorder
CA2559974C (en) * 2004-03-17 2012-08-14 Nestec S.A. Compositions and methods for reducing or preventing obesity
WO2007134867A2 (en) 2006-05-24 2007-11-29 Dsm Ip Assets B.V. Treating muscular disorders and improving muscular function
BRPI0714526A2 (en) 2006-08-24 2013-04-30 Univ Tennessee Res Foundation substituted acylanilides and their methods of use

Also Published As

Publication number Publication date
JP2013507361A (en) 2013-03-04
RU2012118686A (en) 2013-11-20
RU2558534C2 (en) 2015-08-10
BR112012008238A2 (en) 2017-06-06
ES2688447T3 (en) 2018-11-02
CA2776950C (en) 2023-11-21
MX2012004118A (en) 2012-05-08
US9301941B2 (en) 2016-04-05
EP2485740A4 (en) 2013-04-03
WO2011043827A1 (en) 2011-04-14
EP2485740B1 (en) 2018-08-29
AU2010303872B2 (en) 2016-06-23
EP2485740A1 (en) 2012-08-15
JP6122638B2 (en) 2017-04-26
CA2776950A1 (en) 2011-04-14
US20120238515A1 (en) 2012-09-20
AU2010303872A1 (en) 2012-04-19
CN102573857A (en) 2012-07-11

Similar Documents

Publication Publication Date Title
IN2012DN02624A (en)
UA108198C2 (en) Substituted 2-acetamido-5-aryl-l, 2,4-triazolones and their use
IN2012DN00624A (en)
JO3267B1 (en) DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS
IN2012DN00572A (en)
MY161495A (en) Virus like particle compositions and methods of use
MX2010004219A (en) Cd19 binding agents and uses thereof.
WO2009129246A3 (en) Compositions and methods for preparing and using same
MX343135B (en) Fumagillol type compounds and methods of making and using same.
MX2009009761A (en) Compositions and kits for treating influenza.
IN2012DN02177A (en)
IN2012DN02702A (en)
IN2012DN00754A (en)
MX2010003013A (en) Inhibition of angiogenesis.
MX2009010960A (en) Heterocyclic compounds and their methods of use.
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MX2009005725A (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders.
TNSN08400A1 (en) Organic compounds and their uses
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
TN2011000482A1 (en) Organic compounds and their uses
IN2012DN02471A (en)
MX368459B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
MX2013011996A (en) Methods for regulating sirtuin gene expression.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
EA201200428A1 (en) COMPOSITION AND METHOD FOR TREATING OBESITY